Inactivating LATS2 Variation Drives Tumor Progression and Resistance to Anti-PD-1 Therapy in Intrahepatic Cholangiocarcinoma

Key Points

• The aim is to explore the role of LATS2-inactivating variations in intrahepatic cholangiocarcinoma and their implications for therapy.
• Observed clinical associations between LATS2 variation and tumor behavior.
• Analyzed the effect of LATS2 inactivation on anti-PD-1 therapy response.
• Found that LATS2-inactivating mutations correlate with increased tumor progression.
• Demonstrated resistance to anti-PD-1 therapy in cases with LATS2 variations.